Abdalla Hesham M, Dreher Luke, VanDolah Hunter, Bacon Adam, El-Nayir Mohammed, Abdelnabi Mahmoud, Ibrahim Ramzi, Pham Hoang Nhat, Bcharah George, Pathangey Girish, Wheatley-Guy Courtney, Reddy Satyajit, Farina Juan, Ayoub Chadi, Arsanjani Reza
Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA.
Department of Internal Medicine, Trinity Health, Ann Arbor, MI, USA.
Curr Cardiol Rep. 2025 Sep 6;27(1):130. doi: 10.1007/s11886-025-02289-6.
VO₂ max is a fundamental marker of cardiorespiratory fitness with substantial prognostic and diagnostic value within the field of cardiology. This review analyzes current and emerging evidence regarding its clinical uses, highlights key evidence gaps, and explores emerging developments poised to broaden its clinical application.
Evidence supports VO2 max as a powerful independent predictor for heart failure, coronary artery disease, hypertrophic cardiomyopathy, and cardiac amyloidosis, supporting it use in identifying high-risk patients for advanced interventions. Recent developments including the integration of machine learning and wearable devices can facilitate accurate VO2 estimation in routine clinical practice without the necessity of specialized diagnostic tools. Despite its robust diagnostic and prognostic value, VO₂ max assessment remains underutilized in routine cardiovascular care, primarily due to the need for specialized equipment and personnel. Future research should explore emerging technological innovations for VO2 max estimation and the development of evidence-based protocols to support its broader clinical implementation for improved cardiovascular outcomes.
最大摄氧量(VO₂ max)是心肺适能的一项基本指标,在心脏病学领域具有重要的预后和诊断价值。本综述分析了有关其临床应用的现有及新出现的证据,突出了关键的证据空白,并探讨了有望拓宽其临床应用范围的新进展。
有证据支持VO₂ max作为心力衰竭、冠状动脉疾病、肥厚型心肌病和心脏淀粉样变性的有力独立预测指标,支持其用于识别适合进行高级干预的高危患者。包括机器学习和可穿戴设备整合在内的最新进展,可以在无需专门诊断工具的情况下,在常规临床实践中促进VO₂ 的准确估算。尽管VO₂ max评估具有强大的诊断和预后价值,但在常规心血管护理中仍未得到充分利用,主要原因是需要专门的设备和人员。未来的研究应探索用于VO₂ max估算的新兴技术创新,并制定基于证据的方案,以支持其更广泛的临床应用,从而改善心血管疾病的治疗效果。